Evidence map›Paper›PMID 31118556›Full record

ArticleClinical ophthalmology (Auckland, N.Z.)2019

Efficacy and safety of bromfenac 0.09% and sodium hyaluronate 0.4% combination therapy, versus placebo in patients with pterygium I-III for clinical signs on ocular inflammation.

Eduardo Chávez-Mondragón, Claudia Palacio, Abraham Soto-Gómez, Miguel Villanueva-Nájera, Guillermo De Wit-Carter, Ruben Suárez-Velasco, Leopoldo Baiza-Duran, Oscar Olvera-Montaño, Patricia Muñoz-Villegas

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical ophthalmology (Auckland, N.Z.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Eduardo Chávez-MondragónFundación de Asistencia Privada Conde de Valenciana, IAP, CDMX, Mexico.ORCID 0000-0002-3665-0254
Claudia PalacioFundación Hospital Nuestra Señora de la Luz, IAP, CDMX, Mexico.
Abraham Soto-GómezCatarata y Glaucoma de Occidente, SA de CV, Guadalajara, Jalisco, Mexico.ORCID 0000-0003-3588-1322
Miguel Villanueva-NájeraPrivate Office, CDMX, Mexico.ORCID 0000-0001-6324-4748
Guillermo De Wit-CarterAsociación para Evitar la Ceguera en Mexico IAP, CDMX, Mexico.
Ruben Suárez-VelascoNovam y Vita, Guadalajara, Jalisco, Mexico.
Leopoldo Baiza-DuranClinical Research Department, Laboratorios Sophia, SA de CV, Zapopan, Jalisco, Mexico.
Oscar Olvera-MontañoClinical Research Department, Laboratorios Sophia, SA de CV, Zapopan, Jalisco, Mexico.ORCID 0000-0003-2717-349X
Patricia Muñoz-VillegasClinical Research Department, Laboratorios Sophia, SA de CV, Zapopan, Jalisco, Mexico.ORCID 0000-0002-7559-1218
Laboratorios Sophia (Mexico) · MXAsociacion Para Evitar la Ceguera en México Hospital Dr. Luis Sánchez Bulnes · MXSecretaría de Salud de Jalisco · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

conjunctival hyperemianonsteroidal anti-inflammatory drugocular lubricantOcular Surface Disease Index

Identifiers

PMID31118556
PMCPMC6507105
OpenAlexW2943403829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.